Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer
Methodology day presentations - 13 June 2019 Principles underlying the development of NICE guidance - Steven Barnes. An introduction to how health
Everything NICE has said on how community pharmacies can promote health and wellbeing in an interactive flowchart
Everything NICE has said on managing hypertension in adults in an interactive flowchart
NICE apps for android and apple devices. Includes BNF, BNFC and NICE guidance.
Everything NICE has said on diagnosing and managing type 1 diabetes in adults in an interactive flowchart
Everything NICE has said on recognising and managing ovarian cancer in an interactive flowchart
NICE research projects and partners.
Patient access schemes and the NICE Patient Access Liaison Unit When assessing new drugs and treatments, NICE looks at the cost of the treatment and...
Outside interests of the NICE senior management team
NICE has today (23 August 2019) announced its intention to work with GW Pharma to address the issues highlighted by its independent appraisal committee in its evaluation of cannabidiol for treating 2 types of severe treatment-resistant epilepsy.
Workshops to help voluntary and community sector organisations learn more about NICE's activities
Please complete all the required fields before submitting the form.RWE Navigator feedback form 1. Please tell us about yourself. Which
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. Who we are
Chief executive has been at the helm of the institute since it was founded in April 1999
Everything NICE has said on changing people's health-related behaviours, including interventions aimed at over 16s, in an interactive flowchart
Advice from NICE to help you generate evidence to inform future NICE evaluations and to enable market access
Designed for developers of medicinal products and other similarly regulated technologies. Receive advice from NICE, the European Medicines Agency...
Our express service is designed for companies who need to receive scientific advice within more challenging timeframes. Within 12 weeks, you'll...
Scientific advice medtech advice
Designed for developers of medicinal products and other similarly regulated technologies. Allows you to seek joint regulatory advice from the...
Advice on improving the quality of economic models
Training seminars and workshops for those in the pharmaceutical, medical technology or cell and gene therapy sectors
Find out more about why engaging with us early is important. We will: introduce NICE present NICE Scientific Advice explain how to complete the
Book one of our scientific advice team to speak at your event
Designed for those seeking advice in either pharmaceutical or medical technologies. Provides the highest level of detail of all our advice processes.
Feedback from the GP reference panel survey
Promoting independence through intermediate care - a quick guide for staff delivering intermediate care services.
Scientific advice for developers of pharmaceuticals
NICE Evidence Services issues View the latest issues affecting NICE Evidence Services (Healthcare Databases Advanced Search(HDAS), Evidence Search
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults
Everything NICE has said on assessing the risk of, preventing and treating osteoporotic fragility fractures in adults in an interactive flowchart
Everything NICE has said on psoriasis in an interactive flowchart
Everything NICE has said on preventing, identifying, assessing and managing obesity in an interactive flowchart
Everything NICE has said on preventing, diagnosing and managing alcohol-related disorders in an interactive flowchart
This quality standard covers the assessment, management and care provided for people aged 14 and over who have coexisting severe mental illness and substance misuse. It describes high-quality care in priority areas for improvement.
We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the fast track appraisal.
Everything NICE has said on severe mental illness and substance misuse (dual diagnosis) for people over 14 in community services in an interactive flowchart
Everything NICE has said about assessing and managing coexisting severe mental illness and substance misuse in healthcare settings in an interactive flowchart
Recommendation ID NG121/5 Question What is the clinical and cost effectiveness of intermittent auscultation compared with continuous cardiotocography
Recommendation ID NG136/3 Question Are progesterone or progestogens effective in treating threatened miscarriage? Any explanatory notes(if
Recommendation ID NG121/1 Question Does caesarean section protect against cerebral haemorrhage in women with a history of subarachnoid haemorrhage
Recommendation ID NG124/2 Question What is the best technique for delivering surfactant in a minimally invasive manner? Any explanatory
Recommendation ID NG121/4 Question What clinical features and laboratory investigations can be used to better stratify risk for women in
NICE quality standards set out priority areas for quality improvement in health and social care.
Recommendation ID NG124/4 Question Does targeting higher oxygen saturations of 92% to 97% in preterm babies lead to improved survival without...
Recommendation ID NG124/1 Question What is the effectiveness of high-pressure non-invasive positive pressure ventilation (NIPPV) compared
Recommendation ID NG121/3 Question Is obesity an independent risk factor for perinatal morbidity and mortality? Any explanatory notes(if